Skip to main content
    T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $70.99
    -1.30 (-1.80%)

    Market Cap: $3.38B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    +25.88%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.77
    Range$-2.23 - $-1.46
    3 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.20-796.3%
    60d ago$-1.83+3.7%
    30d ago$-1.53-15.2%
    7d ago$-1.54-15.0%
    Current$-1.77
    Revenue Consensus
    $184M
    Range$179M - $194M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-3.41
    Range$-9.27 - $0.21
    3 analysts
    Revenue Consensus
    $219M
    Range$205M - $233M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.41---
    Sep 26EST
    		-$-1.77---
    Jun 26
    Reported Aug 6
    		$-0.43$-0.21-104.76%Miss+10.4%
    Mar 26
    Reported May 6
    		$-0.16N/A+61.90%Beat+75.0%
    Dec 25
    Reported Feb 23
    		$-0.20$-0.08-139.23%Miss+66.7%
    Sep 25
    Reported Nov 4
    		$-0.30$-0.33+9.09%Beat+50.8%
    Jun 25
    Reported Aug 6
    		$-0.48$-0.36-33.33%Miss+42.2%
    Mar 25
    Reported May 1
    		$-0.64$-0.63-1.59%Miss+35.4%
    Dec 24
    Reported Feb 25
    		$-0.60$-0.82+26.44%Beat+54.2%
    Sep 24
    Reported Nov 13
    		$-0.61$-1.00+39.00%Beat+52.0%
    Jun 24
    Reported Aug 8
    		$-0.83$-0.80-3.75%Miss+29.1%
    Mar 24
    Reported May 8
    		$-0.99$-1.25+20.80%Beat-13.8%
    Dec 23
    Reported Feb 27
    		$-1.31$-1.36+3.68%Beat-167.3%
    Sep 23
    Reported Nov 9
    		$-1.27$-1.27+0.00%Beat-51.2%
    Jun 23
    Reported Aug 10
    		$-1.17$-1.02-14.71%Miss-431.8%
    Mar 23
    Reported May 9
    		$-0.87$-0.91+4.40%Beat+9.4%
    Dec 22
    Reported Mar 13
    		$-0.49$-0.69+28.99%Beat+31.9%
    Sep 22
    Reported Nov 9
    		$-0.84$-1.07+21.50%Beat-10.5%
    Jun 22
    Reported Aug 11
    		$-0.22N/A+56.00%Beat-166.7%
    Mar 22
    Reported May 10
    		$-0.96$-1.06+9.43%Beat-304.3%
    Dec 21
    Reported Mar 14
    		$-0.72$-0.73+1.37%Beat-5.9%
    Sep 21
    Reported Nov 9
    		$-0.76$-0.47-61.70%Miss-52.0%
    Jun 21
    Reported Aug 4
    		$0.33$-0.33+200.00%Beat+269.3%
    Mar 21
    Reported May 11
    		$0.47$-0.13+461.54%Beat-
    Dec 20
    Reported Mar 31
    		$-0.68$-0.66-3.03%Miss-
    Sep 20
    Reported Oct 16
    		$-0.50$-0.54+7.41%Beat-
    Jun 20
    Reported Sep 2
    		$-0.19N/A+57.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-65.13EV/EBITDAN/A
    Price/FCF55.01xFCF Yield1.82%
    Profitability
    Profit Margin-7.67%Operating Margin-11.50%
    ROE-13.70%ROIC-9.20%
    Financial Health
    Debt/Equity0.21xInterest Coverage-5.58x
    Current Ratio3.20xQuick Ratio3.17x
    Trading Statistics
    Beta0.45Avg Volume856.60K
    52-Week High$91.5352-Week Low$53.89

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$72.91
    SMA 20$74.76
    SMA 50$74.78
    SMA 200$68.20
    EMA 10$73.03
    EMA 20$74.22
    EMA 50$73.23
    EMA 200$68.00

    MACD

    Line: -1.02Signal: -0.40Hist: -0.63

    ADX

    ADX: 16.5+DI: 18.3-DI: 20.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$76.25

    Bollinger Bands

    Upper Band$79.34
    Lower Band$70.18
    %B Position1224%(Upper)
    Band Width0.09

    RSI (14-Day)

    Neutral
    41.7

    Momentum Oscillators

    Stoch %K13.7
    Stoch %D21.4
    Williams %R-89.4
    ROC (10d)-5.9%
    Momentum-4.47
    CCI (20d)-106.6
    MFI (14d)54.6

    Volatility Measures

    ATR (14d)$3.16(4.5%)
    StdDev (20d)2.29
    Hist Vol35.3%(Moderate)

    Volume Flow

    VWAP$72.16
    OBV9.1M
    AD Line5.6M
    CMF (20d)-0.091

    Volume Metrics

    Avg Vol (20d)885.6K
    Vol Ratio1.1x
    VWMA (20d)$74.60

    Pivot Points

    R3$77.07
    R2$75.21
    R1$73.75
    Pivot Point$71.89
    S1$70.43
    S2$68.57
    S3$67.11

    Advanced Oscillators

    TSI-9.09
    Ultimate Osc36.5
    KST-39.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$173.91M$162.05M$151.67M$118.70M$102.66M$78.33M$66.41M$48.12M$40.81M$27.61M$13.08M$1.87M
    Cost of Revenue$12.11M$9.40M$10.93M$8.31M$6.24M$5.21M$4.93M$3.24M$3.00M$1.65M$1.22M$377,000
    Gross Profit$161.80M$152.66M$140.74M$110.39M$96.42M$73.12M$61.48M$44.88M$37.81M$25.96M$11.86M$1.49M
    Operating Expenses$181.71M$158.78M$148.72M$124.92M$118.61M$99.40M$85.90M$70.04M$71.11M$63.64M$56.31M$42.43M
    R&D$31.01M$22.35M$18.04M$16.28M$15.59M$14.41M$16.87M$12.13M$12.32M$12.07M$13.30M$12.11M
    SG&A$150.70M$136.43M$130.68M$108.63M$103.01M$85.00M$69.03M$57.91M$58.79M$51.58M$43.01M$30.32M
    Operating Income$-19,908,000$-6,122,000$-7,976,000$-14,529,000$-22,184,000$-26,280,000$-24,421,000$-25,162,000$-33,302,000$-37,684,000$-44,450,000$-40,935,000
    Interest Income$6.51M$3.72M$3.95M$4.11M$4.23M$3.45M$3.65M$4.12M$4.13M$3.12M$2.98M$2.84M
    Interest Expense$2.16M$2.13M$2.21M$2.27M$2.24M$2.21M$2.31M$2.44M$4.05M$983,000$989,000$858,000
    Income Before Tax$-15,835,000$-4,615,000$-6,314,000$-12,585,000$-20,340,000$-25,120,000$-23,113,000$-23,420,000$-33,290,000$-35,731,000$-41,902,000$-39,148,000
    Income Tax Expense$2.72M$2.35M$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,551,000$-6,967,000$-8,373,000$-12,585,000$-20,340,000$-25,120,000$-23,113,000$-23,420,000$-33,290,000$-35,731,000$-41,902,000$-39,148,000
    EBITDA$-19,785,000$-6,462,000$-8,376,000$-15,353,000$-23,439,000$-27,076,000$-25,359,000$-25,826,000$-34,325,000$-37,771,000$-43,525,000$-41,305,000
    EBIT$-20,189,000$-6,209,000$-8,050,000$-14,431,000$-22,329,000$-26,361,000$-24,448,000$-25,095,000$-33,367,000$-37,865,000$-43,891,000$-41,130,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TARS

    News

    Liquidity Mapping Around (TARS) Price Events

    This article analyzes Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) with a focus on liquidity mapping and AI-generated trading strategies. It identifies weak near and mid-term sentiment, a neutral long-term outlook...

    Stock Traders Daily•10/14/26•Somewhat-Bearish

    Form S-3ASR Tarsus Pharmaceuticals Inc For: 13 October By Investing.com

    This article announces that Tarsus Pharmaceuticals Inc filed a Form S-3ASR on October 13. The filing is a standard SEC form used by eligible companies for efficient securities registration. The article provides no...

    Investing.com India•10/14/26•Neutral

    Form S-3ASR Tarsus Pharmaceuticals Inc For: 13 October By Investing.com

    This article reports that Tarsus Pharmaceuticals Inc. filed a Form S-3ASR on October 13. The brief notice from Investing.com indicates this financial filing and includes the company's stock symbol TARS. The content...

    Investing.com Nigeria•10/14/26•Neutral

    Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

    Analysts from Barclays and J.P. Morgan have issued bullish sentiments on several healthcare stocks, including Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)...

    The Globe and Mail•10/13/26•Neutral

    Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Profit Outlook

    Tarsus Pharmaceuticals (NASDAQ:TARS) is nearing profitability, with analysts predicting a breakeven in 2027 after a US$46m trailing-twelve-month loss. The company is expected to achieve positive profits of US$6.9m...

    Simply Wall Street•10/9/26•Somewhat-Bullish

    TARS Valuation and Fair Value

    P/E
    -65.1x
    Forward P/E
    68.0x
    P/FCF
    55.0x
    P/B
    8.9x
    See GNG's fair value

    TARS Profitability: Margins, ROIC and FCF

    Gross margin
    93.3%
    Operating margin
    -11.5%
    Net margin
    -7.7%
    ROIC
    -9.2%
    ROE
    -13.7%
    FCF margin
    9.2%
    FCF yield
    1.8%

    TARS Competitors

    CompanyTicker
    CareDx IncCDNA
    Xenon Pharmaceuticals IncXENE
    Viking Therapeutics IncVKTX
    Arcutis Biotherapeutics IncARQT
    Cidara Therapeutics IncCDTX
    Ideaya Biosciences IncIDYA
    Pulse Biosciences IncPLSE
    Warby Parker IncWRBY

    Sector: Healthcare

    TARS Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    1
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TARS Bull Case vs Bear Case

    Bull case

    • TARS grew quarterly revenue 69.4% year over year.
    • 100.0% of TARS's analyst ratings are Buy or Strong Buy.

    Bear case

    • TARS has a -7.7% net profit margin.

    TARS Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -17.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.77
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TARS

    Does TARS pay dividends?

    Tarsus Pharmaceuticals Inc (TARS) does not currently pay a regular dividend.

    What is TARS's market cap?

    Tarsus Pharmaceuticals Inc (TARS) has a market capitalization of $3.38B with a current stock price of $70.99.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In